Nitronal (Glyceryl Trinitrate)

Glyceryl trinitrate releases nitric oxide within vascular smooth‑muscle cells. The nitric oxide activates soluble guanylate cyclase, raising cGMP levels, which relaxes smooth muscle in veins and arteries. This vasodilation reduces cardiac preload and afterload, lowering myocardial oxygen demand and alleviating ischemic chest pain.

The specific dose of Nitronal is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosing is individualized, often starting with a low intravenous infusion that is titrated to achieve the desired hemodynamic effect while monitoring blood pressure and symptoms.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Nitronal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nitronal belongs to the nitrate class, offering rapid venous and arterial dilation. Compared with oral nitrates, the intravenous form provides faster onset and precise titration. Unlike calcium‑channel blockers, nitrates primarily reduce preload, making them especially useful in acute settings, though both classes may be combined under careful monitoring.

Nitronal should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Ensure the container is sealed when not in use, and follow standard aseptic techniques during preparation and administration to maintain sterility.

Nitronal is supplied as an intravenous solution. It is administered by slow IV infusion or bolus injection under continuous hemodynamic monitoring. The infusion rate is adjusted by the clinician to achieve target blood pressure or symptom relief, with frequent assessment of vital signs.

The most serious adverse events include severe hypotension, which can lead to syncope or organ hypoperfusion, methemoglobinemia that impairs oxygen delivery, allergic reactions such as rash or bronchospasm, and life‑threatening arrhythmias. Prompt recognition and immediate management are essential.

Nitronal is contraindicated in patients with severe hypotension, cardiogenic shock, or known hypersensitivity to nitrates. It should also be avoided in individuals taking phosphodiesterase‑5 inhibitors (e.g., sildenafil) because of the risk of profound blood‑pressure drops. Clinicians must assess each patient’s medical history before initiating therapy.